ctt1403
Recombinant proteinexperimentalImaging agent
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2019 (NCT03822871)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Glutamate carboxypeptidase IIINHIBITOR
FOLH1 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
- Imaging
- 177-Lutetium
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03822871 | Phase 1 | Apr 1, 2019 | Cancer Targeted Technology, University of California, San Francisco |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cancer Targeted Technology | For profit | 1 | 1 | 1 | 2019 |
| University of California, San Francisco | Academic/Hospital | 1 | 0 | 1 | 2019 |
2 organizations
Page 1 / 1